A comparison of efficacy and safety of 2-year telbivudine and entecavir treat…

There are limited data comparing the clinical outcomes between telbivudine and entecavir. We consecutively enrolled 115 telbivudine-naive and 115 entecavir-naive chronic hepatitis B patients, who were matched for age, sex, hepatitis B e antigen (HBeAg) status and cirrhosis, and treated for at least 2 years or less than 2 years but had developed resistance. Except for the rate of HBeAg seroconve…

Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in th…

Edition

-

ISBN/ISSN

-

Collation

-

Series Title

-

Call Number

-

Circulating Cytokines and Histological Liver Damage in Chronic Hepatitis B In…

Edition

-

ISBN/ISSN

-

Collation

-

Series Title

-

Call Number

-

Evaluation of serum levels of IL-6, TNF-, IL-10,IL-2 and IL-4 in patients wit…

Changes in various cytokine activities have been reported during both HBV andHCV infections, while an imbalance of pro-inflammatory and anti-inflammatory cytokineproduction influences their immunopathogenesis. The aims of the present study are (a) tomeasure serum levels of interleukin-6 (IL-6), tumor necrosis factor  (TNF-), interleukin-10(IL-10), interleukin-2 (IL-2) and interleukin-4 (IL-4)…

Current Knowledge of Occult Hepatitis B Infection and Clinical Implications

Occult hepatitis B infection (OBI) is a status of undetectable serum hepatitis B surface antigen (HBsAg) yet detectable serum and/or intrahepatic hepatitis B virus (HBV) DNA. Mutations in the preS1, preS2, and S regions of the HBsAg gene may result in undetectable HBsAg. OBI may either result froma self-limiting acute hepatitis, or in patients with chronic hepatitis B who achieved HBsAg serocle…

Efficacy and Safety of Entecavir Versus Adefovir in Chronic Hepatitis B Patie…

A randomized, open-label comparative study of entecavir versus adefovir therapy was performed in subjects with chronic hepatitis B who had hepatic decompensation (Child-Turcotte-Pugh score
7). Adult subjects were randomized and treated (n 5 191) with entecavir 1.0 mg or adefovir 10 mg daily for up to 96 weeks from the date of last subject randomization. Subjects were positive or negative for …

Four-Year Entecavir Therapy Reduces Hepatocellular Carcinoma, Cirrhotic Event…

Oral antiviral therapy may reduce the disease progression of chronic hepatitis B (CHB) patients. We aimed to further investigate the efficacy of long-term entecavir therapy in reduction the risk of hepatocellular carcinoma (HCC), cirrhotic events and mortality in a large group of CHB-related cirrhosis patients

Pharmacotherapy of Chronic Hepatitis B with Entecavir

Actually three nucleotide/nucleoside analogues are used for chronic hepatitis B: lamivudine, adefovir dipivoxil, entecavir and telbivudine. Lamivudine and adefovir are advantageous for oral administration and safety, but they induce a sustained response after withdrawal of therapy in only a minority of patients. Telbivudine is a new drug and further studies are need to evaluate its real effi…

The role of entecavir in the treatment of chronic hepatitis B

Entecavir (ETV) is a potent and selective inhibitor of hepatitis B virus replication. In HBeAg-positive and HBeAg-negative lamivudine-naïve patients with chronic hepatitis B (CHB), treatment with ETV at a dose of 0.5 mg daily is associated with a more potent viral suppression, a higher rate of biochemical remission and a greater improvement of liver histology compared to Lamivudine (LAM).

Comparison of entecavir and adefovir for the treatment of chronic hepatitis B

The results of several new clinical trials that compared the effectiveness of entecavir (ETV) treatment with that of adefovir (ADV) treatment in patients with chronic hepatitis B (CHB) were published in recent years. However, the numbers of patients included in these clinical trials were too small to draw a clear conclusion as to whether ETV is more effective than ADV. Therefore, a new meta-ana…